{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:04:31Z","timestamp":1771707871062,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102492","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:03:04Z","timestamp":1766160184000},"page":"102492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Incidence by Age and Clinicopathological Characteristics: A Population-Based Study in Girona, Spain, 2010 to 2021"],"prefix":"10.1016","volume":"24","author":[{"given":"Arantza","family":"Sanvisens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Trallero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Puigdemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vidal-Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Comet-Batlle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-3657","authenticated-orcid":false,"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat Carles","family":"Serd\u00e0-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102492_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102492_bib0002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0003","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030387","article-title":"Prostate cancer disparities by race and ethnicity: from nucleotide to neighborhood","volume":"8","author":"Rebbeck","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clgc.2025.102492_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2025.102492_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.34622","article-title":"Incidence, prevalence, and survival of prostate cancer in the UK","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102492_bib0006","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102492_bib0007","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/21681805.2018.1534886","article-title":"Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer","volume":"52","author":"Moschini","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2022.01.018","article-title":"The association between age, prostate cancer risk, and higher gleason score in a long-term screening program: results from the G\u00f6teborg-1 prostate cancer screening trial","volume":"82","author":"Godtman","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0009","first-page":"981","article-title":"Predicting pathological stage of localized prostate cancer","volume":"278","author":"Petros","year":"1997","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.clgc.2025.102492_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jval.2021.07.002","article-title":"Systematic review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis","volume":"25","author":"Keeney","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2025.102492_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100993","article-title":"Advances in high-risk localized prostate cancer: staging and management","volume":"47","author":"Reina","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clgc.2025.102492_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298764","article-title":"Prostate cancer in Spain: a retrospective database analysis of hospital incidence and the direct medical costs","volume":"19","author":"Darb\u00e0","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2025.102492_bib0013","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005","volume":"101","author":"Welch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102492_bib0014","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102492_bib0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-021-02230-y","article-title":"Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients","volume":"20","author":"Merriel","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.clgc.2025.102492_bib0016","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1186\/s12889-023-17440-7","article-title":"Significantly reduced incidence and improved survival from prostate cancer over 25 years","volume":"23","author":"Serd\u00e0-Ferrer","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clgc.2025.102492_bib0017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jnci\/djaa068","article-title":"Prostate cancer incidence 5 years after us preventive services task force recommendations against screening","volume":"113","author":"Jemal","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102492_bib0018","series-title":"TNM Classification of Malignant Tumors","year":"2009"},{"key":"10.1016\/j.clgc.2025.102492_bib0019","series-title":"TNM Classification of Malignant Tumors","year":"2017"},{"key":"10.1016\/j.clgc.2025.102492_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1142976","article-title":"Prostate cancer epidemiology and prognostic factors in the United States","volume":"13","author":"Abudoubari","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102492_bib0021","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cncr.32702","article-title":"Age dependence of modern clinical risk groups for localized prostate cancer-a population-based study","volume":"126","author":"Huynh-Le","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102492_bib0022","doi-asserted-by":"crossref","first-page":"pkae106","DOI":"10.1093\/jncics\/pkae106","article-title":"Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019","volume":"8","author":"Owens","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.clgc.2025.102492_bib0023","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277784","article-title":"Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy","volume":"17","author":"Orrason","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2025.102492_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9444","article-title":"Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort","volume":"4","author":"Bergengren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102492_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102492_bib0028","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, Version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2025.102492_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56825","article-title":"Trends in prostate cancer incidence and mortality rates","volume":"8","author":"Van Blarigan","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102492_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.euo.2023.11.002","article-title":"Prognosis of gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study","volume":"7","author":"Egevad","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102492_bib0031","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00428-024-03810-y","article-title":"Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study","volume":"484","author":"Egevad","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2025.102492_bib0032","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cam4.549","article-title":"Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score","volume":"5","author":"Herget","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2025.102492_bib0033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102492_bib0034","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bju.12843","article-title":"Metabolic syndrome-like components and prostate cancer risk: results from the reduction by dutasteride of prostate cancer events (REDUCE) study","volume":"115","author":"Sourbeer","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102492_bib0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/pcan.2017.1","article-title":"Meta-analysis of metabolic syndrome and prostate cancer","volume":"20","author":"Gacci","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102492_bib0036","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/ijc.34116","article-title":"Circulating free testosterone and risk of aggressive prostate cancer: prospective and mendelian randomisation analyses in international consortia","volume":"151","author":"Watts","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2025.102492_bib0037","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s40618-025-02671-9","article-title":"Temporal trends in serum testosterone and luteinizing hormone levels indicate an ongoing resetting of hypothalamic-pituitary-gonadal function in healthy men: a systematic review","volume":"48","author":"Santi","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clgc.2025.102492_bib0038","article-title":"COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review","author":"Mostafavi Zadeh","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.clgc.2025.102492_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182413269","article-title":"Differences in the impact of COVID-19 on pathology laboratories and cancer diagnosis in Girona","volume":"18","author":"Sanvisens","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clgc.2025.102492_bib0040","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/cancers15061753","article-title":"Impact of the COVID-19 pandemic on cancer diagnosis in Madrid (Spain) based on the RTMAD tumor registry (2019-2021)","volume":"15","author":"Garrido-Cantero","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102492_bib0041","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102492_bib0042","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102492_bib0043","series-title":"AJCC Cancer Staging Man. Eight","first-page":"723","article-title":"Prostate","author":"Buyyounouski","year":"2017"},{"key":"10.1016\/j.clgc.2025.102492_bib0044","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.3390\/cancers16203490","article-title":"Advanced imaging for localized prostate cancer","volume":"16","author":"Albers","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102492_bib0045","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/jcm14093067","article-title":"Prostate cancer-research advances in early detection","volume":"14","author":"Czerw","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clgc.2025.102492_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102716","article-title":"Updated cancer burden in oldest old: a population-based study using 2022 Globocan estimates","volume":"95","author":"Shah","year":"2025","journal-title":"Cancer Epidemiol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:29:06Z","timestamp":1771705746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767325001922"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102492","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Incidence by Age and Clinicopathological Characteristics: A Population-Based Study in Girona, Spain, 2010 to 2021","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102492"}}